Page 32 - Project Bioshield News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Soligenix, Inc.: Soligenix Receives Japanese Patent for Improved Production of Synthetic Hypericin Composition PRINCETON, N.J., May 20, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Japan Patent Office has allowed the patent application titled "Systems and Methods for Producing Synthetic Hypericin".  The allowed claims are directed to unique, proprietary methods to produce a novel, hi...

Soligenix Receives Japanese Patent for Improved Production of Synthetic Hypericin Composition Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma News provided by Share this article Share this article PRINCETON, N.J., May 20, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Japan Patent Office has allowed the patent application titled "Systems and Methods for Pr...

Soligenix Announces Recent Accomplishments And First Quarter 2021 Financial Results News provided by Share this article Share this article PRINCETON, N.J., May 17, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2021. "This year continues to be an exciting year of progress for Soligenix," stated Christopher J. Schabe...

Broad Efficacy and Improved Safety Profile of HyBryte™ Presented at Society for Investigative Dermatology Virtual Meeting News provided by Share this article Share this article PRINCETON, N.J., May 4, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Ellen Kim, MD, Medical Director, Dermatology Clinic, Perelman Center for Advanced Medicine, Professor of Dermatology at the Hospital of the Uni...

/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...